News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eli Lilly and Company (LLY) To Shutter Animal Enzyme Plant



8/15/2014 6:59:03 AM

Eli Lilly and Company To Shutter Animal Enzyme Plant Eli Lilly and Company To Shutter Animal Enzyme Plant

August 15, 2014
By Mark Terry, BioSpace.com Breaking News Staff

Indiana-based pharmaceutical giant Eli Lilly and Company (LLY) has announced it will close its Terre Haute animal enzyme manufacturing facility by early 2016. According to Lilly spokesman, Ed Sagebie, the company plans to consolidate all of its animal enzyme facilities to a site in Great Britain.

The Elanco plant closing will affect 23 employees, who will be offered similar positions at the company’s facility in Vermillion County. Elanco is the name of Eli Lilly’s animal health division.

Lilly intends to sell the property. The decision, Sagebiel stated, had nothing to do with the productivity of the facility or the effectiveness of the workers. The intent is to consolidate animal enzyme production to a single location.
  Related Jobs  
  Research Associate - Regeneron Pharma
  Scientist / Assoc. Manager - Regeneron Pharma
  Research Associate - Regeneron Pharma
  Postdoctoral Fellow - Pfizer
  Research Associate - Bristol-Myers Squibb
  Research Scientist - Gilead Sciences
  View More Jobs


Animal feed enzymes help animals digest food more efficiently. The company recently submitted a trademark application for “DEVELOPING ENZYMES THAT COUNT” related to animal feed enzymes and additives.

In addition, in April Lilly announced an agreement to acquire Novartis Animal Health for $5.4 billion. This would make Elanco the second-largest animal health company in the world. Novartis Animal Health had 2013 revenue of $1.1 billion and a presence in 40 countries. As part of the acquisition, Lilly acquired Novartis Animal Health’s nine manufacturing facilities, six R&D facilities, a portfolio of about 600 products, global infrastructure, and more than 3,000 employees. Also, the acquisition brought in a pipeline of about 40 products in development.

Eli Lilly is axing jobs but others are hiring too. Check it out! (Isn't it tempting?)


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES